Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Collyar: What's In It for Patients?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement

Mar

11

Today In Oncology

Stanford Names Leader for Drug Development and Precision Oncology

Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer

Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks

FDA Releases Updated Guidance on Biosimilar Development

SABCS 2025: High-Level Review of Select Data

Advertisement

© 2026 HSP News Service, L.L.C.